Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 9/2012

01-09-2012 | Letter to the Editor

Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia

Authors: Maria Perera, Alexia Suarez, Hugo Luzardo, Jezabel Lopez, Teresa Molero

Published in: Annals of Hematology | Issue 9/2012

Login to get access

Excerpt

Dear Editor, …
Literature
1.
2.
Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ (2010) International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115(2):168–186. doi:10.​1182/​blood-2009-06-225565 PubMedCrossRef
3.
Sailer T, Lechner K, Panzer S, Kyrle PA, Pabinger I (2006) The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy. Haematologica 91(8):1041–1045PubMed
4.
Newland ACL, Eggermann J, Lefrere F, Kreuzbauer G (2011) Sustained hemostatic platelet counts in adult patients with primary immune thrombocytopenia (ITP) following cessation of romiplostim-four European case studies. Haematologica 96(S2)
5.
Bao W, Bussel JB, Heck S, He W, Karpoff M, Boulad N, Yazdanbakhsh K (2010) Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood 116(22):4639–4645. doi:10.​1182/​blood-2010-04-281717 PubMedCrossRef
Metadata
Title
Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia
Authors
Maria Perera
Alexia Suarez
Hugo Luzardo
Jezabel Lopez
Teresa Molero
Publication date
01-09-2012
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 9/2012
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-012-1437-y

Other articles of this Issue 9/2012

Annals of Hematology 9/2012 Go to the issue

Original Article

Increased yet iron-restricted erythropoiesis in postpartum mothers

Original Article

Ophthalmologic outcomes after chemotherapy and/or radiotherapy in non-conjunctival ocular adnexal MALT lymphoma

Letter to the Editor

Rituximab pharmacokinetics in ascites and serum in the treatment of follicular lymphoma with massive ascites

Original Article

Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients

Original Article

Hereditary protein C deficiency in Indian patients with venous thrombosis

Original Article

Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits